Sonrotoclax + Zanubrutinib for Mantle Cell Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.
Who Is on the Research Team?
Diego Villa
Principal Investigator
BCCA-Vancouver Cancer Centre
Robert Puckrin
Principal Investigator
Tom Baker Cancer Centre, Calgary, AB Canada
Are You a Good Fit for This Trial?
This trial is for adults (18+) with mantle cell lymphoma that has come back or not responded after at least one previous treatment. Participants must have measurable disease, be healthy enough for CAR-T cell therapy, and have a life expectancy of at least 6 months.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- CAR-T Cell Therapy
- Sonrotoclax
- Zanubrutinib
Trial Overview
The study tests if adding two oral drugs, sonrotoclax and zanubrutinib, before standard CAR-T cell therapy helps people with relapsed/refractory mantle cell lymphoma. All participants are planned to receive these treatments as part of the trial.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Canadian Cancer Trials Group
Lead Sponsor
BeOne Medicines
Industry Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.